Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azacitidine + lenalidomide + grifola frondosa extract
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous, Intravenous
01
Overview
azacitidine + lenalidomide + grifola frondosa extract is an investigational combination therapy being evaluated by the M.D. Anderson Cancer Center for the treatment of advanced solid tumors and malignancies. This regimen combines the epigenetic modulating effects of azacitidine (a DNA methyltransferase inhibitor) and the immunomodulatory properties of lenalidomide (a cereblon E3 ligase modulator) with a protein-bound beta-glucan polysaccharide extract derived from the Grifola frondosa (maitake) mushroom. The mushroom extract is intended to act as a biologic response modifier, stimulating innate and adaptive immune cells such as macrophages, natural killer (NK) cells, and T cells. The Phase I clinical trial aims to establish the maximum tolerated dose and safety profile of this triplet combination in patients whose cancers are refractory to standard therapies.
- Other names
- Grifola frondosa extractMaitake D-fractionMaitake mushroom extract
02
Targets
DNMT1 (DNA (cytosine-5)-methyltransferase 1)CRBN (Cereblon)
Beyond the preview
Go deeper on azacitidine + lenalidomide + grifola frondosa extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azacitidine + lenalidomide + grifola frondosa extract.